At baseline, our analyses demonstrate that depressive symptoms significantly predicted QoL measured by AcroQoL (p < 0.001) and SF-36 (p < 0.001) in acromegaly in a model including age, gender, disease duration, basal GH levels, tumor size, and possible treatment modalities and comorbidities as covariates. The gene discussed is GH1; the disease is acromegaly.